|
|
2 V3 J: T4 m. A* [
Vaccines, 6th Edition , J6 S! e; \9 ^6 {- R! {$ ^6 G
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.* K( U' V8 n' j; p% h
( k# l! z& ^% Y9 n' M( Thttp://yun.baidu.com/share/link?shareid=2079860221&uk=3810996606; f' u: ^$ U( c* D- }5 }* Y
% e" I9 _+ O0 `! s: G/ c) o
SECTION 1: General aspects of vaccination
. S, r) k+ G5 }1 A short history of vaccination 1- m# \0 [$ V5 z( M; D* K/ o; ~' h
2 Vaccine immunology 14- \! Y) V! T. k
3 The vaccine industry 334 g, Q: p2 o% E* ]
4 Vaccine manufacturing 44
1 R9 w% w; }" H) h5 Evolution of adjuvants across the centuries 58
+ C2 n; c* W. G! ?6 Vaccine additives and manufacturing residuals in the United States:3 ?' Z k2 f9 B" E4 w$ }5 C
licensed vaccines 710 g ~. L5 K; Y2 [6 ~( J
7 Passive immunization 80
7 `/ J1 z6 n: {7 N7 |% B5 d8 General immunization practices 88
3 {9 [2 W4 R1 H/ PSECTION 2: Licensed vaccines7 \. c- _$ B. E7 H+ r
9 Adenovirus vaccines 1130 B9 n2 b1 l/ m1 c6 e ^- A
10 Anthrax vaccines 127( S* v, F4 `% b6 f# o
11 Cholera vaccines 141
1 h& [5 q4 J# a5 ]7 ?9 w8 d" y5 Y12 Diphtheria toxoid 153! r) p4 o( O7 {
13 Haemophilus influenzae vaccines 1678 P# s3 l- x0 l% v* L8 I q
14 Hepatitis A vaccines 183
( @% W( B( R8 V6 }15 Hepatitis B vaccines 205
2 N( w2 j2 O2 U7 x16 Human papillomavirus vaccines 235
7 Y' c5 X# M; J0 p3 p% X: |/ X4 I17 Inactivated influenza vaccines 257
4 r: t* t. ?. a' F; B18 Influenza vaccine-live 294! Z$ N2 [; O2 g; i2 d2 l
19 Japanese encephalitis vaccines 3121 u+ C1 E& B/ s) u
20 Measles vaccines 352: _ ?" L8 U5 {/ F, Z
21 Meningococcal vaccines 3886 }5 ~& s+ y! g: Q9 q5 u
22 Mumps vaccine 419, k! v7 \2 v+ d8 L; O* d! X" t* U
23 Pertussis vaccines . 447
% |3 _: v6 z$ z24 Plague vaccines 493
0 y2 V7 c2 k8 b+ v25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 5049 D7 |& q, }8 d. E. C! ^( F! H6 [
26 Pneumococcal polysaccharide vaccines 542
0 c, [: @& [9 _27 Poliovirus vaccine-inactivated . 573' T8 s6 h! R" E# a" s
28 Poliovirus vaccine-live 598% M5 C2 O4 O) C2 R
29 Rabies vaccines .646
S0 W: p) X2 o" L3 v P30 Rotavirus vaccines . 669
% R$ W+ h% g: E31 Rubella vaccine 688
+ v# l, z, U! I5 e32 Smallpox and vaccinia 718
% `! H0 H$ j* o/ {33 Tetanus toxoid 746- K; w" ~! E# a5 d) I! F
34 Tick-borne encephalitis virus vaccines 773
2 O% e6 ?/ D4 d9 Y& m! M2 B/ l( j5 `& c35 Tuberculosis vaccines 789/ M& M! m) z$ v5 l$ R# i0 R+ q
36 Typhoid fever vaccines 812( U, O, R8 F, S* c
37 Varicella vaccine 837
8 g* O- ^$ b5 x9 }38 Yellow fever vaccine 870
# m8 o' x; ~3 P5 d9 N9 l5 E39 Zoster vaccine 969- N% G2 m, F) U4 a& s4 p
40 Combination vaccines 9819 Z- X Q8 Z, \3 F$ M3 |, G
SECTION 3: Vaccines in development and new vaccine strategies; ~; j& Z6 C9 J* a) W, e; Z+ e
41 Biodefense and special pathogen vaccines 1008! m2 Y) T6 T5 ^5 S" r {
42 Therapeutic cancer vaccines 1018% V: h$ {% e0 |7 }$ ^ Q
43 Cytomegalovirus vaccines 1032
; t( d# U! G% M$ f. }44 Dengue vaccines 1042+ {% ?! @7 ?" j! k7 l @
45 Diarrhea caused by bacteria 1052# I: ~8 O* j4 V4 u! f; T
46 Ebola vaccine 1060. M$ f, |" X/ {( s$ Y
47 Epstein-Barr virus vaccines 10681 s! p6 U6 g5 B3 H+ X3 N4 Y
48 Hepatitis C vaccines 1074* `& d8 O) [4 _; J2 S: U
49 Hepatitis E vaccines 1085
, G/ j$ e9 i5 a9 \50 Herpes simplex virus vaccines 1090
% ]" D, Q/ ?, J( B8 E9 L51 Human immunodeficiency virus vaccines 1097. \0 \. D9 h1 S; g+ {! |$ q+ A5 n- W
52 Lyme disease vaccines 1122 C( ^8 M5 m1 _' a6 c
53 Malaria vaccines 1133
$ o+ F8 g8 e/ j, Q% q( Z3 ^54 Noninfectious disease vaccines 1138( l# ^ g0 W0 `2 f8 p/ B" y
55 Respiratory syncytial virus and parainfluenza virus vaccines 1146
' ? {' m. p# N) B3 ]: c2 G1 b56 Parasitic disease vaccines 1154
1 }. [' E$ X1 d- Z57 Staphylococcus aureus vaccines 1161 |, [7 ]" A% t6 l
58 Streptococcus group A vaccines 1169
3 T5 B p* d, |* Z Z59 Streptococcus group B vaccines 1176, i$ G: p% E" z+ N4 G& g
60 Technologies for making new vaccines 1182
6 l, m) ~3 i6 M% Z% O6 l o61 Alternative vaccine delivery methods 1200
/ C) V1 _2 u% ~! Y62 The development of gene-based vectors for immunization 1232
* ?7 k/ Y+ Y3 fSECTION 4: Vaccination of special groups
# m% r, n( U& m; }5 |6 n1 \$ P63 Vaccination of immunocompromised hosts 12433 F; C' ~7 [, n
64 Vaccination of human immunodeficiency virus-infected persons 12577 F* P$ q* n' l6 p; s+ u X3 ~5 R) b
65 Vaccines for international travel 1270% l8 L. j; B& F* x0 I
66 Vaccines for health care personnel 1290
" v* F, [' _8 [' u- |* iSECTION 5: Public health and regulatory issues7 i6 Z' E+ T# X9 }& ~, @
67 Immunization in the United States 1310
7 {" O" f! |2 f+ z. e6 K5 ]% ] l0 U68 Immunization in Europe . 13342 K# J* E9 d. Y3 w1 i
69 Immunization in the Asia-Pacific region 1353
3 [3 ~ D. m/ \ j6 K% ?70 Immunization in developing countries 1369/ e+ f( X; K2 a% x
71 Community immunity 1395 M4 `0 [' f& F) N
72 Economic analyses of vaccine policies 14136 k, d. q; m) _& I6 J9 V
73 Regulation and testing of vaccines 1427
9 X3 I% C* i9 y( W7 O% q7 ?+ f74 Regulation of vaccines in Europe 1447
; o! B/ p" A6 E" {/ h, a. l7 [& A/ |75 Regulation of vaccines in developing countries 1454
! N- v4 [2 U/ R+ c5 d76 Vaccine safety 1464
* K8 D2 Q- T5 m [& U77 Legal issues . 1481; A% I- [; ~2 z% K; C" }
78 Ethics 1508
* l" i' {+ K& w0 O( O$ [( B1 x/ p' x: T& m# K
. ^' J% n! ~( m0 U) k+ V3 i
$ X' t, R/ j! H7 K4 e( D- D. x1 A& Y5 g$ u- z7 d/ [5 z
|
|